NTRP NEUROTROPE, INC.

19.45
0  -2%
Previous Close 19.84
Open 20.10
Price To book 5.68
Market Cap 144.86M
Shares 7,448,000
Volume 70,280
Short Ratio 0.00
Av. Daily Volume 81,008

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due May 1, 2017.
Bryostatin
Alzheimer's disease

Latest News

  1. Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017
  2. Aegis Ponders Neurotrope's Odds Of Pulling The 'Alzheimer's Sword From The Stone'
  3. Neurotrope Nears Breakthrough in New Alzheimer's Treatment
  4. Neurotrope, Inc. (Nasdaq: NTRP) to Ring The Nasdaq Stock Market Opening Bell
  5. Neurotrope, Inc. Announces Approval for Listing on the NASDAQ Capital Market
  6. Neurotrope's President and Chief Scientific Officer to Present Keynote Address at Sachs Associates' 2nd Annual Neuroscience Biopartnering & Investment Forum
  7. Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
  8. Biotech Movers On Friday: Neurotrope Inc (NTRP) And PTC Therapeutics, Inc. (PTCT)
  9. Neurotrope BioScience to Present at the Oppenheimer 27th Annual Healthcare Conference
  10. Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears
  11. Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia
  12. Neurotrope Bioscience to Present at the 19th Annual BIO CEO & Investor Conference 2017
  13. Neurotrope Bioscience to Present at the Noble Financial Capital Markets' 13th Annual Investor Conference
  14. Neurotrope Announces Reverse Split of Common Stock in Preparation for NASDAQ Uplisting
  15. Neurotrope to Present at Two Upcoming Investor Conferences
  16. Neurotrope, Inc. :NTRP-US: Earnings Analysis: Q3, 2016 By the Numbers : December 27, 2016
  17. Neurotrope Issues Statement On Eli Lilly's Solanezumab
  18. Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimer's Disease
  19. Neurotrope Announces Private Placement of $20 Million
  20. Dr. Daniel Alkon Appointed President of Neurotrope, Inc.